NextCure, Inc.
Close on Oct 19, 2026
- Market cap
- $30.11M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 23, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | Before market open | – | – | – |
Press releases
Announcements NextCure filed with the SEC
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99.1 to Form 8-K
NextCure Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
NextCure and Avere Therapeutics Announce Merger
Material agreement · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cadherin 6 (CDH6) is a transmembrane glycoprotein overexpressed in multiple
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
J U N E 2026
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
NextCure Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
NextCure Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
J A N U A R Y 2 0 2 6
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NextCure Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
NextCure Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
J U N E 2 0 2 5
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
NextCure Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
NextCure’s expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “may,”
Regulation FD disclosure · EX-99.1 to Form 8-K
NextCure Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
Other events · EX-99.1 to Form 8-K
NextCure Announces Acceptance of IND Application for LNCB74
Other events · EX-99.1 to Form 8-K
NextCure’s expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “may,”
Regulation FD disclosure · EX-99.1 to Form 8-K
NextCure’s expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “may,”
Regulation FD disclosure · EX-99.1 to Form 8-K
NextCure Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
NextCure Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
NextCure’s expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “may,”
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
NextCure Provides Year-End Clinical Pipeline Updates
Regulation FD disclosure · EX-99.1 to Form 8-K
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
NextCure Provides Business Update and Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
NextCure Provides Business Update and Reports Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
NextCure Provides Update and Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
NextCure Provides Business Update and Reports
Results of operations · EX-99.1 to Form 8-K
NextCure Provides Business Update and Reports
Results of operations · EX-99.1 to Form 8-K
NextCure Provides Business Update and Reports
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Next Generation Immunomedicines March 2022
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Clinical and Research Updates on NC318 and NC410
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
NextCure Reports Third Quarter 2021 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K